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Abstract
Background: Perception of quality of life may differ depending on the perspective. The aim of the study was to
assess the psychometric properties of the Spanish version of the ‘TOlerability and quality Of Life’ (TOOL)
questionnaire, a specific self-rated instrument to evaluate the impact of side effects of antipsychotic drugs on health-
related quality of life (HRQoL). The questionnaire consists of eight items answered on a four-point Likert scale.
Methods: A psychometric study was conducted with clinically stable outpatients with schizophrenia and bipolar
disorder under antipsychotic treatment. The translation and cultural adaptation of the questionnaire was performed
according to international standards. Internal consistency using the Cronbach a coefficient and test-retest reliability
using the intraclass correlation coefficient (ICC) was used to assess the reliability of the instrument. Patients
completed generic and specific measures of quality of life and clinical severity.
Results: A total of 238 patients were analysed, with a mean age of 42 years (SD 10.9). The mean completion time
was 4.9 min (SD 4.4). Internal consistency and intraclass correlation coefficient were adequate (Cronbach a = 0.757
and ICC = 0.90). Factorial analysis showed a unidimensional structure (a single eigenvalue >1, accounting for 39.1%
of variance). Significant Spearman’s rank correlations between the TOOL and both generic and specific measures
were found. The questionnaire was able to discriminate among the Clinical Global Impression - Severity scores
(Mann-Whitney U test, P < 0.001).
Conclusions: The TOOL questionnaire shows appropriate feasibility, reliability, and discriminative performance as a
patient-reported outcome. TOOL constitutes a valuable addition to measure the impact of adverse events of
antipsychotic drugs from the patient perspective.
Background
Schizophrenia and bipolar disorder are worldwide preva-
lent and severe mental diseases [1,2]. Newer antipsycho-
tic treatments have proven useful in reducing both
relapses and the severity of symptoms [3]. However,
weight gain, extrapyramidal symptoms, sexual dysfunc-
tion, or sedation are quite common side effects among
patients under antipsychotic treatment [4]. The occur-
rence of these symptoms may affect patient adherence
to medication, leading to discontinuation, limiting treat-
ment effectiveness, and increasing both personal and
social costs [5,6]. Therefore, when comparing alternative
therapies, side effects and their impact on patient
health-related quality of life (HRQoL) could be of great
importance in order to define the most efficient antipsy-
chotic drug treatment [3,7].
The systematic assessment of patient perspective may
provide valuable information that could be lost when rely-
ing only on clinical evaluation. In chronic conditions such
as schizophrenia and bipolar disorder, there are advan-
tages in using patient-reported measures to understand
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and clinicians [8]. The importance of involving patients in
their own healthcare, and of patient-reported assessments,
is increasingly recognised [9].
Many efforts have been made to develop or validate
specific instruments to assess patient affectation within
different domains [10-13]. Regarding side effects, the
most widely used and specific measure is the Udvalg for
Kliniske Undersøgelser (UKU) side effects scale [14].
This questionnaire, filled out by clinicians or patients,
comprises 56 items that refer to psychic, neurological,
autonomical and others effects. Despite this scale, more
specific tools in terms of HRQoL are still needed to
afford greater insight in describing and grading the
impact of side effects associated to antipsychotic drugs
[15,16]. A brief instrument is preferred for use in clini-
cal practice and in investigations such as clinical man-
agement studies or clinical trials comparing the
effectiveness of treatments.
A specific measure to assess HRQoL impairment
related to adverse events of antipsychotic drugs has been
previously developed and validated in Sweden: the ‘TOl-
erability and quality Of Life’ (TOOL) questionnaire [17].
This self-rated measure reflects the subjective perception
of side effects in patients treated with antipsychotic med-
ication. It comprises eight attributes and has four levels
per domain (Likert scale: 1 = minimum to 4 = maximum
impact). These domains are mood (worry-upset), func-
tion capabilities, and several adverse events frequently
associated with antipsychotic treatment (fatigue-weak-
ness, weight gain, stiffness-tremor, physical restlessness,
sexual dysfunction, and dizziness-nausea). In contrast to
the Drug Attitude Inventory [10] or the Subjective Well-
being under Neuroleptic scale [11], the TOOL question-
naire was specifically designed to identify from the
patient perspective the most common adverse events of
both typical and atypical antipsychotic drugs [4,18].
T h ea i mo ft h ep r e s e n ts t u d yw a st oe v a l u a t et h el i n -
guistic adaptation and psychometric validation into Span-
ish of the TOOL questionnaire for the assessment of side
effects in patients treated with antipsychotic medication
and their impact on health-related quality of life.
Methods
Linguistic adaptation of the TOOL questionnaire
Forward/backward translations of the original TOOL
questionnaire were completed by expert translators.
Firstly, three independent Spanish experts translated the
original version in Swedish into Spanish. Experts exam-
ined and compared these three different versions in
order to reach a single one by consensus (intermediate
version 1.0). Secondly, one Swedish expert translated
this intermediate Spanish version again into Swedish
(backward translation) and compared his results with
the original version to ensure conceptual equivalence
(intermediate version 2.0). Finally, all the expert transla-
tors participated in the proof reading test of the inter-
mediate version 2.0, and the final Spanish version was
thus established.
Subsequently, the Spanish version was reviewed by a
panel of experts (five psychiatrists and one general prac-
titioner specialised in HRQoL). According to expert cri-
terion, three items were modified to facilitate patient
comprehension: mood, physical restlessness, and dizzi-
ness-nausea. Next, 40 clinically stable patients (20 with
schizophrenia and 20 with bipolar disorder) filled out
the Spanish version of the TOOL. They were also asked
to review this version in terms of comprehension (C)
and importance (I) using a scale ranged from 0 (lowest
level of C/I) to 4 (highest level of C/I). All the items
scored higher than two points (threshold) in both scales.
Consequently, the Spanish version of the TOOL ques-
tionnaire was ready for validation (Additional file 1).
Psychometric validation of the TOOL questionnaire
A multicentre, non-interventional psychometric study
was conducted. The study was carried out at 60 psychia-
tric centres throughout Spain, and was approved by the
institutional review board of the University Hospital of
Salamanca (NCT00692133).
Participants were outpatients treated in community
healthcare centres. Eligibility criteria included being at
least 18 years old, having a Diagnostic and Statistical
Manual of Mental Disorders, 4th Edition, Text Revision
(DSM-IV-TR) diagnosis of schizophrenia or bipolar dis-
order as established by the Structured Clinical Interview
for DSM-IV, being clinically stable (defined as having
had no changes in severity or new treatments initiated
in the last month), and taking a single oral antipsychotic
medication. After complete description of the study to
the participants, written informed consent was obtained.
Investigators completed the following scales: Positive
and Negative Syndrome Scale (PANSS) [19] (only to
patients with schizophrenia), Young Mania Rating Scale
(YMRS) [20] (only to patients with bipolar disorder),
Montgomery-Asberg Depression Scale (MADRS) [21],
Clinical Global Impression - Severity scale (CGI-S) [22],
and UKU Side Effect Rating scale (UKU) [14].
Patients completed the following instruments: (1) The
EuroQol 5-Dimensions (EQ-5D) [23] and Short Form 6-
Dimensions (SF-6D) [24]: taking into account that the
aim of this work is not to obtain utilities but to mea-
sure patient HRQoL, in these multidimensional scales
we used the unweighted scores. In both cases, the
higher the scores, the better the HRQoL, and vice versa.
(2) The Spanish version of the TOOL questionnaire.
The full items of the TOOL questionnaire are shown in
Figure 1.
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visit. In order to analyse the psychometric properties of
the TOOL questionnaire, feasibility, reliability and valid-
ity were studied.
Feasibility
The item response rate of the TOOL questionnaire was
described and completion time was registered as well.
Finally, both floor-ceiling effects were evaluated in an
exploratory analysis of the answers given to the TOOL
distribution and by using percentiles 25, 50 and 75
(Tukey’s Hinges).
Validity
Regarding construct validity, item-total correlation (ITC)
was checked following the criterion of removing items
with a score lower than 0.20 in the discrimination rate. To
assess the dimensionality of the questionnaire, an explora-
tory factorial analysis (extraction criterion of eigenvalue
>1) was also conducted. The Spearman rank correlation
coefficient (rs) between the total score of the TOOL and
those of the EQ-5 D (unweighted) and the SF-6 D
(unweighted) was used to test convergent validity. Correla-
tion was considered to be high for rs ≥ 0.5, moderate for rs
values between 0.3 to 0.5, and low for rs < 0.3. This statis-
tic was also applied to determine the relationship between
the TOOL and the MADRS, YMRS, and UKU scales.
These analyses were performed differentially according to
the two groups resulting from clinical diagnosis (patients
with schizophrenia or bipolar disorder). In addition, rs was
used to study the association between each of the TOOL
items and SF-6 D and EQ-5 D measurements.
In order to evaluate criterion validity, patients were
categorised taking into account the CGI-S to compare
TOOL scores. Accordingly, the collected sample was
divided into two groups: patients with no to mild invol-
vement versus patients with moderate to severe involve-
ment. It was hypothesised that patients with lesser
involvement would obtain lower scores in the TOOL
(that is, lesser side effects and a better HRQoL) than
those patients with worse health status according to
expert criterion. Again, a non-parametric statistic
(Mann-Whitney U test) was used in these comparisons
considering the skewed distribution of data.
Reliability
The internal consistency of the questionnaire was ana-
lysed using Cronbach’s a. Test-retest reliability of the
scores was also examined by computing the intraclass
correlation coefficient (ICC).
Statistical analysis
The sample size was calculated taking into account a
specific objective of calculating multiattribute utility
Figure 1 The ‘TOlerability and quality Of Life’ (TOOL) questionnaire.
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antipsychotic therapy [25]. Thus, the determination was
guided by the estimation of the utility function accord-
ing to which a large number of patients is needed to
maximise the precision and reduce the risk of measure-
ment error. To this end, in the present study a sample
size of about 250 patients was considered. Consequently,
the number of patients required for the validation pro-
cess (5 to 15 patients per item) was ensured, and
hypothetical comparisons between the 2 independent
groups could be established (that is, schizophrenic and
bipolar patients) with 80% power and a 5% significance
level (2-sided tests), involving 68 patients per group.
Data tabulation, database validation and the statistical
analyses were carried out using the statistical packages
SPSS (version 14.0; SPSS, Chicago, IL, USA) and Stata
( v e r s i o n1 0 . 0 ;S t a t a ,C o l l e g eS t a t i o n ,T X ,U S A ) .F o ra l l
statistical tests, a level of 0.05 was considered significant.
Registration
This trial was registered under no. NCT00692133.
Results
A total of 242 patients were included in the study. For
the validation analysis, 238 (121 with a diagnosis of schi-
zophrenia and 117 with bipolar disorder) were studied.
The mean age of the sample was 41.9 years (SD 10.9),
and 63% were males (n = 151). Sociodemographic and
clinical characteristics o ft h es a m p l ea r es h o w ni n
Tables 1 and 2.
The percentage of missing values in each of the items
contained in the questionnaire was less than 5%. The
mean completion time was 4.91 min (SD 4.48). A ceiling
effect was found for the following items: stiffness-tremor
and dizziness-nausea (more than 50% of all patients
reported not being bothered at all by any of these
symptoms).
ITC scores were above 0.2 in all items, and body
weight was the only item with a discrimination index
below 0.3: ITC worry-upset = 0.581; function capabilities
= 0.598; fatigue-weakness = 0.633; weight = 0.284; stiff-
ness-tremor = 0.401; physical restlessness = 0.505; sex-
ual dysfunction = 0.360; dizziness-nausea = 0.345.
Exploratory factorial analysis reflected a unidimensional
structure of the TOOL questionnaire (eigenvalue =
3.331) (Table 3). This dimension explained 39.1% of the
variance. The component matrix is shown in Table 2.
Furthermore, the reliability of this structure in terms of
internal consistency was found to be adequate (Cron-
bach a = 0.757). When test-retest reliability was exam-
ined, the results showed fairly appropriate stability in
the evaluations of patient involvement when no changes
in clinical status were detected by the clinicians (ICC =
0.90). Since unidimensionality had been proven, it was
possible to calculate a global score summarising the
patient level in each of the eight domains. A range of
scores between 8 (minimum impact) to 32 (maximum
impact) was obtained. This total score was also analysed
with respect to generic and specific measures to test
convergent and criterion validity.
Correlations between the TOOL and generic measures
of HRQoL were highly-moderately negative and signifi-
cant (Table 4). These results were also observed when
the TOOL scores of bipolar and schizophrenic patients
were compared separately (Table 4). Negative values in
rs responded to the inverse scoring of the measures. In
addition, the associations between the TOOL items and
the generic measures of HRQoL (Table 4) were negative,
Table 1 Sociodemographic and clinical characteristics of
the sample
Variables Total
n = 238
n (%)
Gender, male 151 (63.4)
Age, mean (SD) 41.9 (10.9)
Median time of treatment, months (SD) 33.50
(34.88)
Marital status, n (%):
Single 133 (55.9)
Married 69 (29.0)
Separated 17 (7.1)
Divorced 12 (5.0)
Widowed 7 (2.9)
Living status:
Alone 28 (11.9)
With parents 109 (46.4)
In a couple 74 (31.5)
Others 24 (10.2)
Working status:
Working full time 44 (18.5)
Working part time 28 (11.8)
Student 5 (2.1)
Unemployed 45 (18.9)
Retired (result of disease) 89 (37.4)
Retired (age) 10 (4.2)
Others 17 (7.1)
Clinical Global Impression Severity (median
score = 3.00):
Normal 23 (9.7)
Borderline mentally ill 18 (7.6)
Mildly ill 79 (33.2)
Moderately ill 81 (34.0)
Markedly ill 32 (13.4)
Severely ill 5 (2.1)
Treatment with atypical antipsychotic drugs 227 (95.4)
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measures, the TOOL questionnaire correlated moder-
ately-highly and significantly with the MADRS. More-
over, regarding CGI-S, correlation was not only
moderate and significant but also higher than the one
found between these scales and the HRQoL generic
measures (Table 5). Correlations between specific
domains of TOOL and related UKU subscales were
positive, significant and mild or moderate (Table 6).
Finally, with the aim of testing criterion validity and
discriminative validity of the TOOL, patients were clas-
sified depending on their CGI-S scores, yielding two
Table 2 Clinical characteristics of the sample
Percentiles
Measures N Mean SD Minimum Maximum 25 50 75
PANSS-positive 134 13.63 6.237 7.00 36.00 9.00 12.00 17.00
PANSS-negative 134 19.91 7.938 7.00 41.00 14.75 19.00 26.00
PANSS-combined 133 -6.11 7.569 -29.00 10.00 -11.00 -6.00 -0.50
PANSS-general psychopathology 134 32.76 12.086 16.00 78.00 22.75 31.50 40.00
YMRS 118 5.61 6.777 0.00 32.00 1.00 3.00 8.25
MADRS 231 11.30 8.026 0.00 42.00 5.00 10.00 17.00
UKU-psychic 229 1.66 1.518 0.00 7.00 0.00 1.00 3.00
UKU-autonomous 224 1.87 1.974 0.00 10.00 0.00 1.00 3.00
UKU-extrapyramidal 233 1.29 1.978 0.00 10.00 0.00 1.00 2.00
UKU-total score 173 6.83 6.019 0.00 37.00 2.50 6.00 9.00
UKU-sexual 198 2.20 2.536 0.00 13.00 0.00 1.00 4.00
TOOL 233 13.462 3.430 8.00 32.00 11.00 13.00 15.00
EQ-5 D (unweighted) 234 0.743 0.248 -0.11 1.00 0.682 0.841 1.00
SF-6 D (unweighted) 236 0.785 0.125 0.39 1.00 0.708 0.793 0.893
EQ-5 D = EuroQol 5-Dimensions; MADRS = Montgomery-Asberg Depression Scale; PANSS = Positive and Negative Syndrome Scale; SF-6 D = Short Form 6-
Dimensions; TOOL = ‘TOlerability and quality Of Life’; UKU = Udvalg for Kliniske Undersøgelser; YMRS = Young Mania Rating Scale.
Table 3 Spanish ‘TOlerability and quality Of Life’ (TOOL) questionnaire construct validity: principal component
analysis and component matrix
Component Initial eigenvalues Extraction sums of squared loadings
Total Percentage of variance Cumulative percentage Total Percentage of variance Cumulative percentage
1 3.131 39.140 39.140 3.131 39.140 39.140
2 0.955 11.934 51.074
3 0.905 11.315 62.388
4 0.846 10.570 72.959
5 0.742 9.279 82.238
6 0.563 7.032 89.269
7 0.443 5.534 94.803
8 0.416 5.197 100.000
Component matrix: Spanish TOOL domains
Component 1
Worry-upset 0.747
Function capabilities 0.759
Fatigue-weakness 0.789
Weight gain 0.392
Stiffness-tremor 0.548
Physical restlessness 0.670
Sexual dysfunction 0.491
Dizziness-nausea 0.481
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patients with moderate or severe involvement. Differ-
ences between these groups of CGI-S in the TOOL and
generic HRQoL scores (Mann-Whitney U test) were sig-
nificant in all cases (P < 0.001). The results highlighted
that patients with no or only mild involvement had
lower TOOL scores and higher EQ-5 D and SF-6 D
scores, indicating a better HRQoL (mild CGI-S: TOOL
= 12.168; EQ-5 D = 0.821; SF-6 D = 0.832). In contrast,
those patients with moderate-severe involvement
showed higher TOOL scores and lower EQ-5 D and SF-
6 D outcomes (moderate-severe CGI-S: TOOL = 14.825;
EQ-5 D = 0.663; SF-6 D = 0.739).
Discussion
Agents involved in health technology research have
incorporated other important aspects to the basic aims
of granting new treatments efficacy and safety, such as
those related to patient subjective perception [9,26].
There is published evidence on the appropriateness and
accuracy of self-assessments or self-report evaluations in
patients suffering from mental chronic illness [27-29].
Despite this, however, recently published studies have
focused on the side effects of antipsychotic drugs and
their relationship with HRQoL by following mainly clini-
cian criterion [30]. Few studies have tried to develop
specific instruments to comprehensively quantify the
impact of side effects on HRQoL based on the patient
perspective. This objective should be of primary impor-
tance, taking into account the high prevalence of side
effects in patients undergoing antipsychotic treatments
and their relationship with adherence to treatment [5].
Our results show that the TOOL questionnaire pre-
sents adequate psychometric characteristics for use in
patients with schizophrenia and bipolar disorder. The
completion time of the questionnaire was low (<5 min)
compared with longer questionnaires such as the UKU
scale. Moderate-high correlations were found in both
Table 4 Spearman rank correlations (rs) between Spanish ‘TOlerability and quality Of Life’ (TOOL) and generic
measures of health-related quality of life (HRQoL)
rs Function
capabilities
Fatigue-
weakness
Weight
gain
Stiffness-
tremor
Physical
restlessness
Sexual
dysfunction
Dizziness-
nausea
EQ-5 D
(unweighted)
SF-6 D
(unweighted)
Worry-upset 0.501** 0.495** 0.204** 0.230** 0.416** 0.225** 0.121 -0.532** -0.537**
Function
capabilities
0.471** 0.211** 0.207** 0.375** 0.306** 0.156* -0.591** -0.642**
Fatigue-weakness 0.222** 0.253** 0.409** 0.291** 0.279** -0.557** -0.565**
Weight gain 0.213** 0.080 0.191** 0.082 -0.225** -0.238**
Stiffness-tremor 0.243** 0.111 0.187** -0.328** -0.277**
Physical
restlessness
0.264** 0.090 -0.422** -0.334**
Sexual dysfunction 0.164** -0.406** -0.382**
Dizziness-nausea -0.224** -0.158*
Spanish TOOL - - - - - - - -0.720** -0.678**
Spanish TOOL
(schizophrenia)
- - - - - - - -0.716** -0.645**
Spanish TOOL
(bipolar disorder)
- - - - - - - -0.720** -0.724**
*Correlation is significant at the 0.05 level (two tailed); **correlation is significant at the 0.01 level (two tailed).
Table 5 Spearman rank correlations (rs) between generic and specific measures of health-related quality of life
(HRQoL)
rs EQ-5 D (unweighted) SF-6 D (unweighted) CGI-S PANSS: general psychopathology MADRS YMRS
Spanish TOOL -0.720** -0.678** 0.399** 0.443** 0.578** 0.239**
EQ-5 D (unweighted) 0.722** -0.306** -0.362** -0.483** -0.209*
SF-6 D (unweighted) -0.386** -0.516** -0.663** -0.100
CGI-S 0.578** 0.601** 0.351**
PANSS: general psychopathology 0.758** 0.462
MADRS 0.321**
*Correlation is significant at the 0.05 level (two tailed); **correlation is significant at the 0.01 level (two tailed).
CGI-S = Clinical Global Impression - Severity; EQ-5 D = EuroQol 5-Dimensions; MADRS = Montgomery-Asberg Depression Scale; PANSS = Positive and Negative
Syndrome Scale; SF-6 D = Short Form 6-Dimensions; TOOL = ‘TOlerability and quality Of Life’; YMRS = Young Mania Rating Scale.
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and specific clinician-rated measures as the MADRS,
PANSS, and YMRS, as well as a negative relationship
with generic quality of life instruments (EQ-5 D and SF-
6D), thus highlighting the convergent validity of this
instrument. These correlations were also similar to
those found in other studies analysing the association
between generic and specific measures [31]. Criterion
and discriminative validity were proven by the signifi-
cant differences found int h eT O O Lb e t w e e nt h o s e
patients with mild involvement and patients with mod-
erate-severe symptoms. Thus, patients suffering a worse
health status according to the CGI-S obtained higher
scores in the TOOL, which indicates a more severe
impact on their HRQoL, as has been previously under-
scored [32,33].
The one-dimensional construct of the TOOL, along
with its internal consistency and test-retest reliability,
have been proven, thus allowing clinicians to obtain a
simple and global score (ranging from 8 to 32) with the
same interpretation in terms of severity as the general-
ised UKU scale.
Despite these results, this study presents some limita-
tions that should be considered. A ceiling effect was
observed in two items: stiffness-tremor and dizziness-
nausea. This may be due to the idiosyncrasy of the
population sample collected in the present study: clini-
cally stable patients under drug treatment, based mainly
on atypical antipsychotic agents. Although similar ceil-
ing effects have been reported in other studies [31,32],
these items should be tested in further investigations
with schizophrenic and bipolar patients showing a worse
health status in order to test discriminative power. The
characteristics of the sample may limit the scope of use
of this measure. Therefore, it may be arguable whether
patients with greater involvement (that is, patients with
severe negative symptoms or patients suffering a maniac
episode) could provide reliable reports when completing
the questionnaire. Although there is evidence supporting
the accuracy of such measurement, as has been com-
mented above, the questionnaire should be applied
within such populations to test its psychometrical prop-
erties. Secondly, it is necessary to analyse the sensitivity
of the TOOL in detecting changes in longitudinal
studies.
Conclusions
The Spanish validation of the TOOL questionnaire
shows appropriate feasibility, reliability, and discrimina-
tive performance as a patient-reported outcome to be
used for the assessment of the impact of side effects on
patient health-related quality of life. This information
could be very important to improve therapeutic alliances
and treatment adherence among patients with schizo-
phrenia and bipolar disorder.
Additional material
Additional file 1: TOOL Spanish version. The Spanish version of the
‘TOlerability and quality Of Life’ (TOOL) questionnaire.
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